Contact this trialFirst, we need to learn more about you.
MEK inhibitor
Mirdametinib for Brain Tumor
Recruiting1 awardPhase 1 & 2
Memphis, Tennessee
This trial tests mirdametinib, a drug that blocks cancer growth signals, in children and young adults with specific types of brain tumors. It aims to see if the drug is safe and effective in slowing down or stopping tumor growth. Mirdametinib has been tested in studies for neurofibromatosis type 1-related plexiform neurofibromas.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service